IRON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IRON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Disc Medicine's Enterprise Value is $1,522.18 Mil. Disc Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-84.21 Mil. Therefore, Disc Medicine's EV-to-FCF for today is -18.08.
The historical rank and industry rank for Disc Medicine's EV-to-FCF or its related term are showing as below:
During the past 4 years, the highest EV-to-FCF of Disc Medicine was 2.16. The lowest was -22.19. And the median was 0.00.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-11), Disc Medicine's stock price is $65.93. Disc Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.980. Therefore, Disc Medicine's PE Ratio (TTM) for today is At Loss.
The historical data trend for Disc Medicine's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disc Medicine Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
EV-to-FCF | - | -1.43 | -3.61 | -14.26 |
Disc Medicine Quarterly Data | |||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial | -11.70 | -14.26 | -16.69 | -11.29 | -11.59 |
For the Biotechnology subindustry, Disc Medicine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Disc Medicine's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Disc Medicine's EV-to-FCF falls into.
Disc Medicine's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 1522.179 | / | -84.208 | |
= | -18.08 |
Disc Medicine's current Enterprise Value is $1,522.18 Mil.
Disc Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disc Medicine (NAS:IRON) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Disc Medicine's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 65.93 | / | -3.980 | |
= | At Loss |
Disc Medicine's share price for today is $65.93.
Disc Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.980.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Disc Medicine's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
William Richard White | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
William Jacob Savage | officer: Chief Medical Officer | C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Kevin Bitterman | director | C/O POLARIS VENTURE PARTNERS, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451 |
Mona Ashiya | director, 10 percent owner | C/O SIERRA ONCOLOGY, INC., 2150 - 885 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA Z4 V6C 3E8 |
Atlas Venture Fund X, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Joanne Bryce | officer: Chief Financial Officer | C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472 |
Rahul Khara | officer: General Counsel | C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472 |
Brian Richard Macdonald | officer: Chief Innovation Officer | C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN MA 02472 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Ai Dmi Llc | 10 percent owner | C/O ACCESS INDUSTRIES, INC., 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Atlas Venture Associates Opportunity I, Llc | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates Opportunity I, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Atlas Venture Associates X, Llc | 10 percent owner | 400 TECH. SQ., 10TH FLOOR, CAMBRIDGE MA 02139 |
Access Industries Holdings Llc | 10 percent owner | C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019 |
From GuruFocus
By Marketwired • 11-08-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 11-12-2024
By GuruFocus Research • 03-23-2024
By GuruFocus Research • 02-07-2024
By Marketwired • 11-01-2024
By Marketwired • 05-30-2024
By GuruFocus Research • 09-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.